Amicus buys Celenex for up to $452mm, acquiring ten rare disease pipeline programs
Supporting its business strategy to move into the gene therapy arena, Amicus Therapeutics Inc. agreed to acquire privately held Celenex (gene therapies for neurological lysosomal storage disorders (LSDs)), gaining ten rare disease pipeline projects.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.